- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Pharmaceutical Product Development, Inc.’s (PPDI) Fourth-Quarter Review
Recent Articles by Ed Liston
- Regulators Failed During The Financial Crisis Due To Complacency; Alan Greenspan (JPM)
- Court Asks Fed To Disclose Records Of $2 Trillion U.S. Loan Program Launched After Lehman Collapse (OPY)
- Boeing (BA) Plans To Raise Production Of 777s And 747s Sooner-Than-Expected
- Metabolix, Inc. (MBLX) Maintains Market Weight Rating
- Pressure Mounts On EU To Create A System To Handle Failure Of Large Banks
Analyst Color
- General Growth Properties (GGP) Is Back In Favor
- JPMorgan Raises Its Estimates For Intel (INTC, JPM)
- Metabolix, Inc. (MBLX) Maintains Market Weight Rating
- Brean Murray Carret & Co. Believes Pullback In Bruker Represents Opportunity (BRKR)
- EnerNOC, Inc. (ENOC) Maintains Overweight Rating
Company News
- Tiffany Reports Earnings Monday Morning (TIF)
- Carl Icahn Makes Hostile Takeover Bid For Lions Gate Entertainment (LGF)
- Ex-Cadbury Executive To Head Kraft’s Confectionery Unit (KFT)
- Morningstar Acquires Realpoint LLC (MORN)
- Pfizer Eyes German Drug Maker Stada (PFE, TEVA)
Earnings
- Tiffany Reports Earnings Monday Morning (TIF)
- Top Performing Industries For March 19 (CNC, HANS, CAJ, BBY, GENT)
- CTAS Well Positioned To Pursue Acquisitions
- Stocks That Created New 52-Week Highs (LOPE, HBOS, HDSN, ITMN, INET)
- Benzinga’s Volume Movers (CTEL, IPSU, HANS, TEVA, TRMB)
Markets
- USD Starting a New Wave Up?
- Carter Worth Says Best Buy Losing Momentum (BBY)
- Icahn Offers To Purchase All Outstanding Shares Of Lions Gate (LGF)
- Biotech Stock Mailbag: Generex (PFE, MNKD)
- VIX Lurching Higher Off Historical Support On Greece Worries (VIX)
Analyst Ratings
Posted on 02/09/10 at 10:48am by Ed Liston
Analysts at Barclays Capital (ADR) (NYSE: BCS) have released a report reviewing the fourth-quarter at Pharmaceutical Product Development, Inc. (NASDAQ: PPDI). The company reported results for the fourth-quarter yesterday.
The company reported EPS, depending on how one makes adjustments, somewhere between $0.15 (GAAP), and $0.24, which excludes charges, but not normalizing the tax rate. The company reported surprisingly strong revenue for the quarter. The revenue trends were driven by the recent booking orders. Operating margins in the CRO softened to 15%, down 270 basis points from the third-quarter.
According to analysts, the fourth-quarter bookings mostly benefited from a weaker US dollar. Analysts at Barclays Capital have a 2-Equal Weight rating for Pharmaceutical Product Development, Inc., with a price target of $22.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
- Citigroup May Drop Out Of Bharti Airtel Syndicate (C, BCS)
- Federal Judge Rules Theflyonthewall.com Misappropriated Investment Bank Recommendations (MS, BCS)
- Barclays Looking For An American Acquisition (BCS)
- Stock Market News for March 11, 2010 - Market News
- Regional Bank Stocks Rally (BCS, CMA, FITB, STI)
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
